SG11201900132QA - Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy - Google Patents
Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacyInfo
- Publication number
- SG11201900132QA SG11201900132QA SG11201900132QA SG11201900132QA SG11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- neoepitopes
- rule
- disease
- pct
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000037451 immune surveillance Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016067348 | 2016-07-20 | ||
| PCT/EP2017/068226 WO2018015433A2 (en) | 2016-07-20 | 2017-07-19 | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900132QA true SG11201900132QA (en) | 2019-02-27 |
Family
ID=59399416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900132QA SG11201900132QA (en) | 2016-07-20 | 2017-07-19 | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
| SG10201912678QA SG10201912678QA (en) | 2016-07-20 | 2017-07-19 | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912678QA SG10201912678QA (en) | 2016-07-20 | 2017-07-19 | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190189241A1 (da) |
| EP (2) | EP3488443B8 (da) |
| JP (2) | JP7171543B2 (da) |
| KR (2) | KR102516166B1 (da) |
| CN (2) | CN117757931A (da) |
| AU (1) | AU2017299162A1 (da) |
| BR (1) | BR112018077122A8 (da) |
| CA (1) | CA3031003A1 (da) |
| CY (1) | CY1124551T1 (da) |
| DK (1) | DK3488443T3 (da) |
| ES (1) | ES2890424T3 (da) |
| HR (1) | HRP20211443T1 (da) |
| HU (1) | HUE056660T2 (da) |
| IL (2) | IL311369A (da) |
| LT (1) | LT3488443T (da) |
| MX (4) | MX2019000733A (da) |
| PL (1) | PL3488443T3 (da) |
| PT (1) | PT3488443T (da) |
| RS (1) | RS62390B1 (da) |
| SG (2) | SG11201900132QA (da) |
| SI (1) | SI3488443T1 (da) |
| WO (1) | WO2018015433A2 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224710A (zh) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
| WO2019031939A2 (ko) * | 2017-08-10 | 2019-02-14 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| SG11202002711WA (en) * | 2017-10-12 | 2020-04-29 | Nantomics Llc | Cancer score for assessment and response prediction from biological fluids |
| CN109294983A (zh) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | 一种lff2细胞 |
| CN111402954B (zh) * | 2019-01-02 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种辨识与预测空间辐射损伤防护药靶相关人类基因的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
| ATE449193T1 (de) | 2006-04-12 | 2009-12-15 | Medical Res Council | Verfahren zur bestimmung der kopienummer |
| CA2697045C (en) | 2007-08-21 | 2019-12-31 | Washington University | Improved alzheimer's diagnosis |
| CN101821619B (zh) | 2007-09-07 | 2015-02-11 | 弗卢丁公司 | 拷贝数变化确定、方法和系统 |
| KR102447139B1 (ko) * | 2010-05-14 | 2022-09-23 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| WO2014014498A1 (en) | 2012-07-20 | 2014-01-23 | Verinata Health, Inc. | Detecting and classifying copy number variation in a fetal genome |
| US10738355B2 (en) | 2011-05-24 | 2020-08-11 | Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh | Individualized vaccines for cancer |
| WO2013071154A1 (en) * | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| WO2013120509A1 (en) * | 2012-02-13 | 2013-08-22 | Ruebben Albert | Algorithm for modification of somatic cancer evolution |
| KR101795124B1 (ko) | 2012-04-05 | 2017-12-01 | 비지아이 다이어그노시스 씨오., 엘티디. | 복제 수 변이를 검측하기 위한 방법 및 시스템 |
| MX364370B (es) * | 2012-07-12 | 2019-04-24 | Persimmune Inc | Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas. |
| EP2984598A1 (en) | 2013-03-06 | 2016-02-17 | Life Technologies Corporation | Systems and methods for determining copy number variation |
| CN105377292A (zh) * | 2013-04-07 | 2016-03-02 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| US20150331992A1 (en) * | 2014-05-15 | 2015-11-19 | Ramot At Tel-Aviv University Ltd. | Cancer prognosis and therapy based on syntheic lethality |
| KR20180087246A (ko) | 2015-10-12 | 2018-08-01 | 난토믹스, 엘엘씨 | 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법 |
| RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| WO2018005276A1 (en) * | 2016-06-29 | 2018-01-04 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
-
2017
- 2017-07-19 IL IL311369A patent/IL311369A/en unknown
- 2017-07-19 WO PCT/EP2017/068226 patent/WO2018015433A2/en unknown
- 2017-07-19 RS RS20211138A patent/RS62390B1/sr unknown
- 2017-07-19 HR HRP20211443TT patent/HRP20211443T1/hr unknown
- 2017-07-19 IL IL264203A patent/IL264203B1/en unknown
- 2017-07-19 CA CA3031003A patent/CA3031003A1/en active Pending
- 2017-07-19 KR KR1020197002010A patent/KR102516166B1/ko active IP Right Grant
- 2017-07-19 JP JP2019502699A patent/JP7171543B2/ja active Active
- 2017-07-19 PT PT177433117T patent/PT3488443T/pt unknown
- 2017-07-19 ES ES17743311T patent/ES2890424T3/es active Active
- 2017-07-19 MX MX2019000733A patent/MX2019000733A/es unknown
- 2017-07-19 SI SI201730919T patent/SI3488443T1/sl unknown
- 2017-07-19 CN CN202311634920.4A patent/CN117757931A/zh active Pending
- 2017-07-19 SG SG11201900132QA patent/SG11201900132QA/en unknown
- 2017-07-19 DK DK17743311.7T patent/DK3488443T3/da active
- 2017-07-19 SG SG10201912678QA patent/SG10201912678QA/en unknown
- 2017-07-19 PL PL17743311T patent/PL3488443T3/pl unknown
- 2017-07-19 AU AU2017299162A patent/AU2017299162A1/en active Pending
- 2017-07-19 LT LTEPPCT/EP2017/068226T patent/LT3488443T/lt unknown
- 2017-07-19 KR KR1020237002958A patent/KR20230019223A/ko not_active Application Discontinuation
- 2017-07-19 US US16/318,895 patent/US20190189241A1/en active Pending
- 2017-07-19 EP EP17743311.7A patent/EP3488443B8/en active Active
- 2017-07-19 EP EP21178672.8A patent/EP3967324A1/en active Pending
- 2017-07-19 HU HUE17743311A patent/HUE056660T2/hu unknown
- 2017-07-19 CN CN201780044824.0A patent/CN109477149A/zh active Pending
- 2017-07-19 BR BR112018077122A patent/BR112018077122A8/pt unknown
-
2019
- 2019-01-17 MX MX2023009371A patent/MX2023009371A/es unknown
- 2019-01-17 MX MX2023009369A patent/MX2023009369A/es unknown
- 2019-01-17 MX MX2023009370A patent/MX2023009370A/es unknown
-
2021
- 2021-09-14 CY CY20211100808T patent/CY1124551T1/el unknown
-
2022
- 2022-11-02 JP JP2022176504A patent/JP2023009120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201901364VA (en) | Engineered target specific nucleases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201908513RA (en) | Peptides for treatment of diabetes | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof |